B
BCRX icon

Braidwell’s BioCryst Pharmaceuticals BCRX Stock Holding History

Braidwell’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,379,577
Closed -$17.2M – 78
2024
Q1 		$17.2M Sell
3,379,577
-2,338,900
-41% -$13.2M 0.55% 54
2023
Q4 		$34.3M Buy
5,718,477
+355,497
+7% +$2.06M 1.26% 31
2023
Q3 		$38M Buy
5,362,980
+2,571,100
+92% +$18.5M 1.2% 34
2023
Q2 		$19.7M Buy
2,791,880
+846,746
+44% +$6.79M 0.64% 54
2023
Q1 		$16.2M Buy
+1,945,134
New +$18.7M 0.54% 58

Other funds holding BCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $22.1B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
Caligan Partners New York $1.41B AUM 518.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return